MOONLAKE IMMUNOTHERAPEUTICS Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
MOONLAKE IMMUNOTHERAPEUTICS (MLTX) had Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net of $5.57 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Debt › Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet · last filed 2026-08-10
- 2026-06-30: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $5.57M.
- 2026-03-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $5.94M.
- 2025-12-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $4.52M.
| Period end | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net |
|---|---|
| 2026-06-30 | $5.57M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $5.94M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $4.52M 10-Q · filed 2026-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |